Production of recombinant non-structural protein-3 hydrophobic domain deletion (NS3ΔHD) protein of bluetongue virus from prokaryotic expression system as an efficient diagnostic reagent

Development of ELISA for the detection of antibodies against VP2 protein of bluetongue virus serotype-1

Serotype-specific diagnosis of bluetongue virus (BTV) is necessary for sero-surveillance and taking effective control measures. The VP2 is the major serotype determining protein and BTV-1 is the most predominant serotype in India. In the present study, an indirect ELISA (i-ELISA) was optimized for the detection of serotype-specific antibody against BTV-1 serotype. The VP2 protein of BTV-1 was expressed in a prokaryotic expression system and used to optimize i-ELISA to detect VP2 antibodies of BTV-1 in serum samples of both small and large ruminants. Serum samples (n = 363) classified as positive and negative for antibodies to BTV-1 by serum neutralization test (SNT) and also positive and negative for BTV antibodies by c-ELSIA kit (VMRD, USA) were used to determine the cut-off value, diagnostic sensitivity (DSn), and diagnostic specificity (D-Sp) using receiver operating characteristic (ROC) analysis. The percent positivity (PP) value >30.10% was accepted as the cut-off for i-ELISA at which DSn of 99.52% and D-Sp of 99.35% was observed with a 95% confidence interval. Further, there was no cross-reactivity with other available BTV serotypes in the country. The study indicated serotype-specific i-ELISA is sensitive, specific and suitable alternative to tedious SNT method for determining serotype. The assay will also help in the serotype-specific epidemiological studies and implementation of future control strategies including vaccination and selection of suitable serotype as a vaccine candidate.

A colloidal gold immunochromatographic strip assay for the rapid detection of Shigella in milk and meat products

Anti-Shigella mAb was produced using IpaC and an immunochromatographic strip was developed to detect different serotypes of Shigella in food.

Development of recombinant NS1-NS3 antigen based indirect ELISA for detection of bluetongue antibodies in sheep

Bluetongue is an insect borne (Culicoides) viral disease of small ruminants. The virus blankets the globe with a wide serotypic variation, numbered from 1 to 28. In India 21 different serotypes have been reported to be circulating across the various agro-climatic zones of the country. Non-structural proteins (NSPs) of bluetongue virus have always remained ideal target for differentiation of infected from vaccinated animals. The current study is an extrapolation of our previous work where a novel fusion construct comprising of bluetongue viral segment NS1 and NS3 was successfully cloned, expressed, purified with an efficient strategy for its suitable implementation as a diagnostic antigen. In this study, the applicability of the fusion construct has been further evaluated and optimised for field applicability. The fusion construct used in an ELISA platform projected a relative diagnostic sensitivity and specificity of 98.1% and 95.5% respectively against a pre-established test panel. The rNS1-NS3 ELISA showed substantially good agreement with the commercial BTV antibody detection kit. Finally, the study brings together the diagnostic capability of two NSPs, which can be a handy tool for sero-surveillance of bluetongue.

A critical challenge in the development of antibody: Selecting the appropriate fragment of the target protein as an antigen based on various epitopes or similar structure

The main challenge in the development of antibody is to select the appropriate antigen particularly when a truncated protein is used for immunization or as vaccine antigen. In previous studies, fragment selection was mainly based on epitopes and less often on the structure. Fewer studies have paid attention to the prediction of the truncated protein 3D structure and retained its similarity in the native and truncated proteins. Here we used in silico analysis to select two fragments of Pyruvate Kinase M2 (PKM2), as a tumor marker. One fragment, M-tPKM2, had a shorter sequence with one epitope although the predicted 3D structure was similar to the native PKM2. The other fragment, R-tPKM2, had a longer sequence and thus more epitopes, but had a different structure from the native PKM2. Recombinant truncated proteins were expressed in E. coli and purified via affinity chromatography. Secondary structure elements in purified proteins were determined by Circular Dichroism, then they were utilized to develop antibodies in mice. Both antigens could elicit high immune response against themselves (OD₄₅₀ = 3.326 ± 0.562 for M-tPKM2; OD₄₅₀ = 3.562 ± 0.110 for R-tPKM2). However, significantly higher response against PKM2 was observed among the mice immunized with M-tPKM2 (p < 0.0001 by One way ANOVA followed by Tukey's post hoc comparison). Also, the monoclonal antibody produced against the M-tPKM2 could recognize the native PKM2 in the MCF7 cells. Our finding suggested that for the purpose of designing an antigen with the ability to produce a potent antibody against the target protein, it is better to select sequences which have a similar structure in truncated and native proteins, even at the cost of having shorter sequences and fewer epitopes.

An efficient production of hybrid recombinant protein comprising non-structural proteins (NS 1 & NS 3) of bluetongue virus in prokaryotic expression system

Strategic design and suitable purification techniques are of paramount importance in the production of recombinant proteins, if intended for use in a diagnostic assay. However, there is no single protocol that can be universally adopted for obtaining proteins in requisite quality and quantity across various platforms. In this study, we have targeted proteins of bluetongue virus (BTV), which is the causative agent of an arthropod-borne infectious disease in ruminants. Traditionally, serological diagnosis of the disease has rested upon either virus neutralization test or on an ELISA test that employed a recombinant structural (VP1, VP7) protein. Among the non-structural (NS) proteins of BTV, NS1 and NS3, are preferred candidate antigens in development of immuno-diagnostics as these provide the option for identifying recent/ongoing infection. However, the difficulty in production/purification of recombinant full length NS proteins of BTV in sufficient quantity and quality in various expression systems, due to inherent structural complexities, have restricted their wider applicability as immunodiagnostic reagents. To circumvent the difficulties associated with production/purification, we developed a novel NS1 and NS3 fusion gene (∼1302 bp) encoding for NS1 N-terminus (₁M to G₂₅₂ aa) and NS3 protein containing the N- and C-termini with a deletion of two hydrophobic domains along with intervening variable central domain (₁₁₈A to A₁₈₂ aa) of bluetongue virus 23. This construct was cloned, over-expressed and efficiently purified by single step affinity chromatography under unique denaturing/renaturing condition. The purified fusion protein was found suitable for detection of antibodies against BTV in an indirect ELISA (iELISA).

Immuno-reactivity of recombinant non-structural protein 3 N-terminus (rNS3Nt) in indirect-ELISA for detection of bluetongue viral antibodies in serum samples

Bluetongue, an arthropod borne non-contagious disease of ruminants especially sheep, is caused by bluetongue virus (BTV). Detection of BTV antibodies in susceptible hosts is considered to be of significance in disease diagnosis and differentiation. In the present study, a partial NS3 gene encoding for non-structural protein-3 N-terminus (1MT117 aa) of BTV-23, produced as purified recombinant NS3Nt fusion protein (~32 kDa) using prokaryotic expression system (Escherichia coli), was evaluated as a candidate antigen in an indirect-ELISA (rNS3Nt-ELISA) to measure the serologic response to NS3 protein in small ruminants. The rNS3Nt fusion protein obtained in sufficient quantity and quality has good reactivity in detecting NS3 specific antibodies in field serum samples by indirect-ELISA. As NS3 protein is highly conserved, rNS3Nt-ELISA has potential for NS3 specific detection of antibodies in BTV affected animals irrespective of different viral serotypes. In comparison to structural protein (VP7) based c-ELISA kit and i-ELISA kit, the diagnostic sensitivity (85.1%, 86.2%) and specificity (92.5%, 93.2%) of rNS3Nt-ELISA were found to be relatively lower, respectively. Nevertheless, the study indicated the potential utility of rNS3Nt-ELISA as an alternate assay in routine sero-diagnosis of BTV infection and possible sero-surveillance of ruminants under DIVA strategy.

Co-administration of recombinant major envelope proteins (rA27L and rH3L) of buffalopox virus provides enhanced immunogenicity and protective efficacy in animal models

Buffalopox virus (BPXV) and other vaccinia-like viruses (VLVs) are causing an emerging/re-emerging zoonosis affecting buffaloes, cattle and humans in India and other countries. A27L and H3L are immuno-dominant major envelope proteins of intracellular mature virion (IMV) of orthopoxviruses (OPVs) and are highly conserved with an ability to elicit neutralizing antibodies. In the present study, two recombinant proteins namely; rA27L (₂₁S to E₁₁₀; ∼30 kDa) and rH3L(₁M to I₂₈₀; ∼50 kDa) of BPXV-Vij/96 produced from Escherichia coli were used in vaccine formulation. A combined recombinant subunit vaccine comprising rA27L and rH3L antigens (10 μg of each) was used for active immunization of adult mice (20μg/dose/mice) with or without adjuvant (FCA/FIA) by intramuscular route. Immune responses revealed a gradual increase in antigen specific serum IgG as well as neutralizing antibody titers measured by using indirect-ELISA and serum neutralization test (SNT) respectively, which were higher as compared to that elicited by individual antigens. Suckling mice passively administered with combined anti-A27L and anti-H3L sera showed a complete (100%) pre-exposure protection upon challenge with virulent BPXV. Conclusively, this study highlights the potential utility of rA27L and rH3L proteins as safer candidate prophylactic antigens in combined recombinant subunit vaccine for buffalopox as well as passive protective efficacy of combined sera in employing better pre-exposure protection against virulent BPXV.